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ABSTRACT
Our aim was to assess hepatic functionality in patients with HCC and candidate for liver 
resection.  We  used  dynamic  tests  of  liver  functionality  Indocyanine  green  (ICG)  and 
Hippurate ratio, for the evaluation of surgical risk and postoperative clinical course. 
The clinical and predictive value of the tests  has been compared with each other and with 
routine tests. Tests have been performed on 11 patients with HCC, in 8 before surgery and 
after 6 months, in 1 before TACE and after 6 months. The results showed a significative 
correlation with the endpoints: survival, liver failure, general condition of the patients,  and 
parallelism in  the  clinical  assessment  of  patients.  ICG and Hippurate  ratio  are  useful  in 
patients undergoing liver resection and in the follow up.    
Introduction
Hepatocellular carcinoma (HCC) is the most common liver malignancy. It is in fifth place 
among  malignant  tumors  and  the  third  cause  of  death  for  cancer  rfr.  Altckrose  S.F.,  
Reichman M.E. (2009),  with a male/female ratio 7/1. The worldwide incidence is 714,600 
cases per year  rfr. Jong-Wook L. (2003), 71% in men. The incidence is also increasing in 
developed countries; in the United States in the last two decades there has been an increase of 
80%, greater in blacks than in whites rfr. Montaldo G.et al. (2002); El-Serag H.B., Mason  
A.C. (1999).
80% of cases affects China, Africa and South East Asia; HCC is responsible for 600,000 
deaths every year rfr. Kerstin S., et al. (2009); Gomaa A.I. et al. (2008) . 
In Italy incidence is 5,800 cases in 2002, prevalence 4,300; the trend of incidence in 2007 is 
5,500-6,000 cases, prevalence 4,000; in 2012, 6,600 and 4,230 cases respectively rfr. Bosetti  
C., et al. (2009); mortality rate is 5.7 /100,000 in males, 1.9 /100,000 in females rfr. Bosetti  
C., et al. (2009).
In the majority of cases (80-90%), HCC develops on the basis of liver cirrhosis. HCC can 
also develop in the presence of pre-cirrhotic  liver diseases or even in healthy liver.  Risk 
factors include: HCV infection, which represents the major risk factor in Western World and 
USA, and HBV infection; combined HCV and HBV infections; combined HBV and HDV 
infections;  the  association  of  HCV  and  schistosomiasis;  alcoholism,  nonalcoholic 
steatohepatitis,  obesity,  exposure to exogenous toxic subsances,  in particular  aflatoxin-B1 
and pesticides; metabolic syndrome, diabetes rfr. Gomaa A.I. et al. (2008). In patients HBV+ 
predictors of HCC are: HBe Ag positivity, high viral load and genotype C. rfr. Altckrose SF, 
Reichman ME (2009).
An additional factor is exposure to aflatoxin B-1, that can be an independent cause of hepatic 
damage and hepatocellular carcinoma rfr. Dufour JF, Johnson P. (2009) 
The  disease  that  most  frequently  develops  into  HCC  is  HCV-related  chronic  hepatitis, 
usually  through the  evolution  into  cirrhosis.  It  is  estimated  that  10-30% of  HCV-related 
hepatitis develops into HCC, with an increased annual risk of 1-2% . In many countries 30% 
of HCC is HCV+, while positivity in general population is 1%. rfr. Dufour JF, Johnson P.  
(2009). The genotype 1b is the most frequently associated to HCC rfr. Bruno S. et al. (2007). 
The suspicion of HCC arises from ultrasound image of one or more intrahepatic nodules 
especially  in  patients  with  liver  cirrhosis,  and  from  increased  alpha-fetoprotein.  The 
diagnosis  is  established  with  the  following  investigations:  ultrasound,  CT  angiography, 
volumetric CT, MRI with specific contrast. In doubtful cases ultrasound-guided liver biopsy. 
The choice of the treatment depends on the size of the tumor, the presence of a single nodule 
or multiple nodules, the localization of the hepatic functional reserve, the patient's general 
conditions, the stage of the disease, Child and Meld's evaluation  rfr Capussotti L. Child and 
Meld (2005), Poon R.T.P. (2007).
Surgical  resection  is  the  treatment  of  choice  in  patients  with  HCC  not  suitable  for 
transplantation; only single nodules with maximum diameter less than 5 cm or three nodules 
with diameter ≤ 3 cm each are resectable. According to EASL / AASLD guidelines nodules 
with maximum diameter more than 5 cm are resectable in patients with good liver function 
rfr.  Bruix  J.,  Sherman M.  (2005);  Bruix  J.,  et  al.  (2001).  For  the  execution  of  surgical 
resection is necessary an adequate hepatic functional reserve, ≥ 40%  rfr. Bege T. (2007);  
Liapi E., Geschwind JF (2006). 
For large lesions or multinodular tumors with more than 3 unresectable nodules, TACE can 
be  practiced  rfr.  Bruix  J.,  Sherman  M.  (2005);  Liapi  E.,  Geschwind  JF  (2006); 
www.exvascular.com  ;  Sofarenib  has  been  proposed  as  palliative  chemotherapy  in 
unresectable and non-transplantable patients rfr. Llovet JM., Et al. (2008).
Aim of the research
We intended to evaluate the hepatic functional capacity using dynamic tests (Indocyanine 
green and Hippurate ratio) in patients with HCC, candidates for major liver resection; the 
perioperative mortality and the risk of liver failure after surgical resection in relation to the 
extension  of  resection;  the risk of  liver  failure  in  treatments  with  portal  embolization  in 
preparation for major resection;  rfr. Purcell, R., et al. (2006) any differences in functional 
activity in relation to the etiology of the liver disease evolved into HCC; to compare the 
predictive value of the two dynamic tests.
Materials and methods
 
The research, conducted with the approval of the research project by the Ethics Committee 
(July 10, 2008), has been implemented in the following structures: Sapienza University of 
Rome-Policlinico Umberto I: UOC of Internal Medicine E, Medical Therapy and Thermal 
Medicine,  Department  of  Internal  Medicine  and  Medical  Specialties,  UOC  of 
Gastroenterological  and  Hepatobiliary  Surgery,  Department  of  Surgery  “Pietro  Valdoni”; 
UOC of Anesthesiology and Intensive Care of the Department of Cardiovascular, Respiratory 
and Morphological  Sciences;  Department  of  Chemistry,  “Sapienza”  University  of  Rome; 
National  Institute  of  Health,  Department  of  Veterinary  Public  Health  and  Food  Safety- 
Department of Methodology and Indicators for the Chemical Safety in Food Chains.
We enrolled 11 patients with HCC, M 6 – F 5, mean age 73, range 65-89. 7 of them were 
HCV+, 2 HBV +, 2 negative for HBV and HCV. None of the patients reported alcohol abuse, 
10 patients were classified as Child A and 1 as Child B; 8 patients showed Meld from 3 to 6, 
1 Meld 9, 1 Meld 8, 1 Meld 7; moreover catheterization of hepatic veins and hepatic biopsy 
were also performed in 3 cases. According to Multidimensional Geriatric Assessment (MGA 
1-3) 8 patients were MGA 1, 3 MGA 2. According to the Evaluation of the Association of 
Anesthesiologists  (ASA  1-5),  8  patients  were  ASA  1,  2  were  ASA  2,  1  patient,  not 
undergoing surgery, was ASA 3. All patients underwent endoscopy to assess the presence 
and / or the size of esophageal varices, and / or the presence of gastropathy / ulcers.
The diagnosis of HCC was performed by ultrasonography, CT angiography, volumetric CT, 
MRI with specific contrast.  For diagnosis and treatment,  guidelines of the European Ass. 
Study of Liver were followed rfr. Bruix J., et al. (2001) and of the American Ass. of Liver 
Disease (AASLD 2005) rfr. Bruix J., Sherman M. (2005)
The patients were classified according to the Cancer of the Liver Italian Program (CLIP) rfr  
(2000),  United  Intern.  Consensus  Committee  (UICC),  modified  according  to  AHPBA, 
Barcelona Clinic Liver Cancer (BCLC) cfr. Grieco A., et al. (2005), Llovet JM., et al. (1999). 
For the evaluation of diagnostic and prognostic significance, we considered the following 
criteria: perioperative mortality, liver failure, general condition of patients and survival. We 
enrolled 11 patients: 8 underwent liver resection, 1 TACE, 2 died of intercurrent causes.
Dynamic tests were performed before surgery and then six months after in 6 of the 8 operated 
patients,  2 operated  patients  are  waiting for  check up;  in  1 patient  they were performed 
before and six months after TACE. 
The  ICG,  administered  intravenously  at  a  dose  of  0.5  mg/kg,  was  measured  as  PDR 
percentage-minute of elimination  of indocyanine green from plasma (v.n.>14%) after  15' 
with Limon equipment at the UOC of Anaesthesia and Intensive Care. rfr. R. Purcell et al.  
(2006); Sheng QS. et al. (2004).
Hippurate  Ratio  was  determined  after  intake  of  PABA  orally,  mg  5/Kg  dosed  as  the 
percentage of transformation of p-amnobenzoic acid (PABA-vit. B10-) into p-aminohippuric 
acid (Hippurate Ratio v.n.>20%), a sample was taken (time T0) before PABA intake, and 
after 30' (tempo T1) rfr. Hemming AW, et al. (2001), Linda LY, et al. (1988). 
Samples were assayed by high-resolution chromatographic method (HPLC) at the National 
Institute of Health, Department of Veterinary Public Health and Food Safety; synthesis and 
control of the purity of a precursor of PABA, p-acetamid hippuric acid, were performed by 
chemical  analysis  of  the  elements,  mass  spectrometry  and  MRI  at  the  Department  of 
Chemistry.
Analytical list of patients
Table. 1
PT BD SEX VIRUS 
B-C
ANGIO  CT
MRI
WITH 
SPECIFIC 
CONTRAST 
VOLU
METRIC 
TC
CHILD MELD ICG 
PRE 
TREAT
PABA
 PRE 
TREAT
SURGERY 
TACE
ICG 
POST
TREAT
PABA
 POST 
TREAT
ECO/CT/MRI 
CHECK UP
SIX 
MONTHS 
FOLLOW 
UP
RF 30/07/30 M HCV+ NODULE 
HCC 
SEG VI/VII
SIZE 5CM
A 6 PDR 
20.4
33.00% RESECTION 
SEG VII
APR 
2011
PMA 06/08/45 F HBV+ NODULE 
HCC 
SEG V/VI
SIZE 4CM
A 6 PDR 
25.5
35.00% RESECTION 
SEG VI
DEC
2010
GF 02/08/40 M HCV+ NODULE 
HCC 
IRREGULA
R 
MARGINS 
SEG 
VII/VIII 
SIZE 5CM
A 6 PDR 
15.3
35.00% RESECTION 
SEG VII/VIII
PDR 21.1 36.00% OUTCOME OF 
RESECTION IN 
SEG VII/VIII 
JAN
2010
CF 11/07/42 M NEG NODULE 
HCC 
SEG VIII 
V+IV
SIZE 11CM
VOL 
570.89C
C
H 
10.80CM
A 7 PDR 
35.5
40.00% RIGHT 
HEPATECTO
MY TO SEG 
IV
PDR 21.6 37.00% COMPENSATORY 
HYPERTRPHY  OF 
THE LOBE ON 
WIDELY 
HOMOGENEOUS 
PARENCHYMA
APR
2010
DMC 15/07/30 F HCV+ NODULE 
HCC 
EXOPHYTI
C
SEG IV
SIZE 4CM
A 8 PDR 
26.8
40.00% RESECTION 
SEG IV  B
PDR 26.2 40.00% COMPENSATORY 
HYPERTRPHY  OF 
RESIDUAL 
WIDELY 
HOMOGENEOUS 
PARENCHYMA
MAY
2010
CI 31/05/21 F HCV+ NODULE 
HCC 
EXOPHYTI
C
SEG III
SIZE 4CM
A 9 PDR 
11.2
18.00% RESECTION 
SEG III
PDR 5.4 15.00% FINELY NON- 
HOMOGENEOUS 
ECHOTEXTURE 
FREE FROM 
IMAGES OF 
FOCAL 
PATHOLOGY
SEPT
2010
GV 31/03/34 F HCV+ NODULE 
HCC 
EXOPHYTI
C
SEG III
SIZE 4CM
A 6 PDR 
12.8
18.00% RESECTION 
SEG III
PDR 10.6 18.00% FINELY NON- 
HOMOGENEOUS 
ECHOTEXTURE 
REGULAR V8P 
AND PORTAL 
VEIN
SEPT
2010
RA 27/06/42 M HCV+ NODULE 
HCC 
SEG V
SIZE 4CM
A 6 PDR 
17.8
30.00% RESECTION 
SEG V + 
WEDGE
PDR 20.6 34.00% SLIGHT 
HEPATOMEGALY 
FIBROTIC SCARS 
FROM PREVIOUS 
SURGERY
OCT 
2010
DUS 08/12/22 F HBV 
HCV+
NODULE 
HCC 
SEG VII/VII
SIZE 
7..5CM
A 4 PDR 
10.9
20.00% DEAD
VG 30/07/37 M HCV+ NODULE 
HCC 
SEG 
VII/VIII
SIZE 8CM
VOL 
261.68C
C 
H 
8.90CM
A 6.5 PDR 
20.9
40.00% DEAD
BG 15/05/39 M HBV+ NODULE 
HCC 
SEG VI/VII
SIZE 5.5CM
B 8 PDR 
5.3
18.00% CHEMOEMB PDR 4.6 15.00% MAY 
2009
1) V.G., M, age 71, HCC of cm8 in segment VII and VIII in HCV+. ICG-PDR 20.9, 
PABA 40%, indicative of good hepatic compensation; Child A, Meld 6.5, MGA 1, ASA 2.
The patient died for bone metastases.
Table.2  ICG before treatment 
2) D.S., F,  87 years, HCC of 7.5cm in segment VII and VIII in HBV and HCV negative;
ICG-PDR 10.9, PABA 20%, indicative of modest hepatic compensation; Child A, Meld 3, 
MGA 2, ASA 3. 
The patient died for brain metastases.
3) BG, M, 70 years, HCC of 5.5 cm in segment VI and VII in HBV +, ICG-PDR 5.3, PABA 
18%, indicative of reduced hepatic compensation. Child B, Meld 8, VMG 2, ASA 2. The 
presence of portal hypertension, underlined by catheterization of the hepatic veins, indicated 
the chemoembolization of the lesions. Six months after treatment ICG-PDR 4.6, 15% PABA 
showed no significant changes.
Table.3  ICG before treatment
4) GF, M, 69 years, 5cm HCC in segment VII in HCV+, ICG-PDR 15.3, PABA 35%, 
indicative of good liver compensation. Child A, Meld 6, VMG 1, ASA 1. Six months after 
surgical  resection  of  the  segment  VII  adjusted  for  saving  and  small  resection  of  the 
diaphragm ICG-PDR 21.1, PABA 36%, data indicative of improved liver function.
Table. 4     trabecular HCC                  Table.5  CT angiography after surgery
5)  CF,  M, 67  years,  10cm HCC in segment  VII  and  VIII;  ICG-PDR 35.5,  PABA 40% 
indicative of good liver compensation. Child A, 7 Meld, MGA 1, ASA 1. Six months after 
right hepatectomy (segments V and VIII) extended to IV b and I 9   ICG-PDR 21.6, PABA 
37%, data indicative of preserved liver function
Table.6  CT volumetric study                 Table.7 Arteriography pre-chemioemb.
6) Di  MC, F, 69 years, 3.5 cm HCC in segment IV in HCV +, ICG-PDR 26.8, PABA 40% 
indicative of good liver compensation. Child A, Meld 6, MGA 1, ASA 1. 6 months after 
surgical resection of segment IV ICG-PDR 26.2, PABA 40%, data indicative of  preserved 
liver function 
7) CJ, F, 89 years, HCC of 4cm in segment III in HCV+; ICG-PDR 11.2, PABA 18% 
indicative of moderate liver function. Child A, 9 Meld, MGA 1, ASA 1. After 6 months from 
the resection of segment III ICG-PDR 5.4, PABA 15%, data indicative of decreased liver 
function.
Table. 8 
8) GV, F, 75 years, HCC of 4 cm in segment III in HCV+; ICG-PDR 12.6, PABA 18%, 
indicative of moderate liver activity.  Child A, Meld 6, MGA 2, ASA 1. After six months 
from the resection of segment III, ICG-PDR 10.6, PABA 15%, data indicative of preserved 
liver function.
9) RA, M, 68 years, 4cm HCC in segment V in HCV+; ICG-PDR 17.8, PABA 30% showing 
good liver function. Child A, Meld 6, MGA 1, ASA 1. After six months from the wedge 
resection of the segment V ICG-PDR 20.6, PABA 34%, data indicative of very good liver 
function
10) PMA, F, 65 years, 4cm HCC in segment V and VI in HBV +, ICG-PDR 25.5, PABA 
35% indicative of good liver function. Child A, Meld 6, MGA 1, ASA 1.
She underwent resection of segment VI on June 15, 2010, and  is waiting for check up after 
6 months.
11) RF, M, 80 years, HCC of 5cm in segment VII in HCV+; ICG-PDR 20.4, PABA 33%, 
showing good liver function. Child A, Meld 6, MGA 1, ASA 1. ALT 33, AST 29, gamma-
GT 33, PT 107%, alpha-fetoprotein 489. He underwent resection of segment VII on October 
12, 2010, and is waiting for check up after 6 months.
Table. 9   Pre-surgery CT angiography Table. 10   Trabecular HCC 
Results  
Dynamic tests, ICG and Hippurate ratio, were outside the normal range in 3 out of 9 treated 
patients;  8 patients  underwent  surgical  resection,  1  TACE. Mean pre-treatment  values  in 
operated patients were: ICG - PDR 19.9, range 11.2 - 35.5, PABA 19.9 range 18% - 40%; in 
the patient undergoing TACE: ICG-PDR: 5.3,  PABA 18%. Mean post-treatment values  in 
operated patients: ICG - PDR 19.2 range 5.4 - 26.2; PABA 17.6%, range 15% -37%. Post-
TACE treatment: ICG - PDR: 4.6, PABA 15% .
Discussion
Dynamic tests have proved to correlate well with the considered end points: perioperative 
mortality,  survival,  liver failure,  general  conditions  of patients,  and the results  of routine 
tests: blood count, GOT, GPT, bilirubin, total protein, albumin, compared to which they have 
a higher predictive value. A strong correlation between the two tests has been underlined, 
without significant differences in the occurrence of liver failure, in contrast to what reported 
by Hemming et al. in favour of Hippurate ratio. The correlation shown by dynamic tests with 
the event “death” in the perioperative period (normal test, except one, no deaths), confirms 
what was highlighted in the cases studied by Hemming et al; the good correlation with Child 
classifications  rfr.  Child  CG.  ,  Turcotte  JG.  (1964) and  Meld  classifications  rfr  Meld.  
Kamath PS., et al. (2001) confirms what stated in other studies rfr. Lao XM, et al. (2004);  
Sheng QS., et al. (2004.)
Finally, the favorable course of the studied patients must be noticed, although advanced age 
is  considered as a  risk factor  in  major  liver  resection  rfr.  Fan ST (2002);  Capussotti  L.  
(2005).  Therefore,  we recommend the execution of dynamic tests in elderly patients with 
HCC suitable  for surgery;  ICG and Hippurate  Ratio  tests  are  useful  in the evaluation  of 
patients  with HCC undergoing liver resection and follow-up. The patient  who underwent 
TACE showed no significant changes in testing 6 months after treatment.
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